Free Trial

Pharvaris (PHVS) Competitors

Pharvaris logo
$15.57 +0.09 (+0.58%)
Closing price 03/27/2025 04:00 PM Eastern
Extended Trading
$16.02 +0.45 (+2.92%)
As of 03/27/2025 05:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PHVS vs. ALVO, IMVT, VKTX, RYTM, SRRK, CRNX, MRUS, PTGX, APLS, and BHVN

Should you be buying Pharvaris stock or one of its competitors? The main competitors of Pharvaris include Alvotech (ALVO), Immunovant (IMVT), Viking Therapeutics (VKTX), Rhythm Pharmaceuticals (RYTM), Scholar Rock (SRRK), Crinetics Pharmaceuticals (CRNX), Merus (MRUS), Protagonist Therapeutics (PTGX), Apellis Pharmaceuticals (APLS), and Biohaven (BHVN). These companies are all part of the "pharmaceutical products" industry.

Pharvaris vs.

Pharvaris (NASDAQ:PHVS) and Alvotech (NASDAQ:ALVO) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, community ranking, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

Pharvaris currently has a consensus target price of $40.50, indicating a potential upside of 160.12%. Alvotech has a consensus target price of $18.00, indicating a potential upside of 73.75%. Given Pharvaris' higher probable upside, equities analysts plainly believe Pharvaris is more favorable than Alvotech.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pharvaris
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
Alvotech
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Pharvaris received 29 more outperform votes than Alvotech when rated by MarketBeat users. Likewise, 66.67% of users gave Pharvaris an outperform vote while only 50.00% of users gave Alvotech an outperform vote.

CompanyUnderperformOutperform
PharvarisOutperform Votes
36
66.67%
Underperform Votes
18
33.33%
AlvotechOutperform Votes
7
50.00%
Underperform Votes
7
50.00%

Pharvaris has a net margin of 0.00% compared to Alvotech's net margin of -123.47%. Alvotech's return on equity of 0.00% beat Pharvaris' return on equity.

Company Net Margins Return on Equity Return on Assets
PharvarisN/A -38.52% -36.69%
Alvotech -123.47%N/A -35.87%

In the previous week, Alvotech had 13 more articles in the media than Pharvaris. MarketBeat recorded 15 mentions for Alvotech and 2 mentions for Pharvaris. Pharvaris' average media sentiment score of 0.87 beat Alvotech's score of 0.58 indicating that Pharvaris is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pharvaris
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Alvotech
2 Very Positive mention(s)
4 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Pharvaris has higher earnings, but lower revenue than Alvotech. Alvotech is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PharvarisN/AN/A-$109.18M-$2.80-5.56
Alvotech$391.87M7.97-$551.73M-$1.85-5.60

Pharvaris has a beta of -3.02, suggesting that its share price is 402% less volatile than the S&P 500. Comparatively, Alvotech has a beta of -0.16, suggesting that its share price is 116% less volatile than the S&P 500.

Summary

Pharvaris beats Alvotech on 8 of the 14 factors compared between the two stocks.

Remove Ads
Get Pharvaris News Delivered to You Automatically

Sign up to receive the latest news and ratings for PHVS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PHVS vs. The Competition

MetricPharvarisPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$814.16M$6.91B$5.64B$8.06B
Dividend YieldN/A2.73%4.57%4.01%
P/E Ratio-5.567.2023.1319.03
Price / SalesN/A226.01383.8993.17
Price / CashN/A65.6738.1634.64
Price / Book1.966.476.944.33
Net Income-$109.18M$141.90M$3.20B$247.06M
7 Day Performance1.10%-3.20%-2.33%-0.37%
1 Month Performance-2.08%-5.64%2.84%-3.85%
1 Year Performance-32.63%-7.47%10.74%1.27%

Pharvaris Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PHVS
Pharvaris
1.4367 of 5 stars
$15.57
+0.6%
$40.50
+160.1%
-33.7%$814.16MN/A-5.5630Gap Up
ALVO
Alvotech
2.0025 of 5 stars
$11.31
+0.1%
$18.00
+59.2%
-18.3%$3.41B$391.87M-6.111,026Earnings Report
News Coverage
IMVT
Immunovant
2.4856 of 5 stars
$20.02
+2.6%
$42.90
+114.3%
-42.2%$3.40BN/A-7.64120
VKTX
Viking Therapeutics
4.3386 of 5 stars
$29.83
-3.4%
$97.67
+227.4%
-68.6%$3.35BN/A-29.8320Analyst Forecast
RYTM
Rhythm Pharmaceuticals
4.4437 of 5 stars
$52.34
+2.7%
$69.31
+32.4%
+28.0%$3.31B$130.13M-12.09140Analyst Revision
SRRK
Scholar Rock
3.504 of 5 stars
$34.72
+0.3%
$40.86
+17.7%
+115.9%$3.29B$33.19M-14.77140Analyst Forecast
Insider Trade
CRNX
Crinetics Pharmaceuticals
4.314 of 5 stars
$35.20
+2.1%
$72.64
+106.4%
-21.4%$3.28B$1.04M-9.44210Analyst Forecast
Positive News
MRUS
Merus
2.2027 of 5 stars
$47.22
+0.3%
$85.31
+80.7%
+0.2%$3.26B$36.13M-11.9537
PTGX
Protagonist Therapeutics
3.601 of 5 stars
$53.01
-3.2%
$61.22
+15.5%
+73.6%$3.25B$434.43M19.93120Positive News
APLS
Apellis Pharmaceuticals
4.354 of 5 stars
$25.11
+1.8%
$45.53
+81.3%
-58.5%$3.15B$781.37M-12.37770Positive News
BHVN
Biohaven
3.9184 of 5 stars
$29.73
+2.0%
$63.15
+112.4%
-50.3%$3.03BN/A-3.18239
Remove Ads

Related Companies and Tools


This page (NASDAQ:PHVS) was last updated on 3/28/2025 by MarketBeat.com Staff
From Our Partners